Praxis Precision Medicines (PRAX) is back in focus after the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to elsunersen for seizures linked to rare SCN2A developmental and epileptic encephalopathy.

The Breakthrough Therapy news lands after a very strong run for Praxis Precision Medicines, with the share price at $308.94 and recent moves mixing a 9.43% 7 day share price return with a 1 month share price decline of 11.88%. Multi year total shareholder returns are very large, suggesting sentiment swings around both growth potential and clinical and regulatory risk.

If this kind of biotech catalyst has your attention, it could be a good time to look beyond a single stock and see what else is moving through 38 healthcare AI stocks

With Praxis Precision Medicines trading at $308.94 and screening tools flagging an intrinsic discount and a very large multi year total return, the key question is whether investors are still underestimating its pipeline or already pricing in future growth.

Most Popular Narrative: 31.2% Undervalued

At a last close of $308.94 versus a most followed fair value estimate of $449.13, the current Praxis Precision Medicines share price sits well below what the narrative suggests, framing the latest FDA catalyst against an already optimistic long term view.

Multiple late stage epilepsy programs, including vormatrigine and relutrigine with breakthrough designation in severe genetic epilepsies, create a portfolio effect in a growing CNS innovation cycle. This increases the probability of multiple approvals and a step change in total company earnings over the back half of the decade.

Want to see what sits behind that earnings step change idea? The most followed narrative leans heavily on aggressive revenue expansion, margin improvement and a rich future earnings multiple. Curious which assumptions really move that $449.13 fair value and how they fit together over the next few years?

Result: Fair Value of $449.13 (UNDERVALUED)

However, Praxis Precision Medicines still carries clear risks, including the possibility that pivotal epilepsy trials underperform early data or that future financing needs dilute existing shareholders.

Next Steps

With the mixed sentiment around Praxis Precision Medicines, it makes sense to move quickly, compare your assumptions with the numbers, and decide where you stand using the 2 key rewards and 2 important warning signs

Looking for more investment ideas beyond Praxis Precision Medicines?

If you stop with Praxis Precision Medicines, you could miss other stocks that fit your goals. Put the screeners to work and broaden your opportunity set today.

• Spot potential upside by scanning for companies that currently look mispriced using the 44 high quality undervalued stocks.
• Prioritize resilience by focusing on businesses with strong finances through the solid balance sheet and fundamentals stocks screener (48 results).
• Hunt for under followed opportunities with quality fundamentals via the screener containing 18 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.